瀏覽量: 111
- 產(chǎn)品名稱(chēng): Mirvetuximab soravtansine
- 產(chǎn)品貨號(hào): CS132258
- 貨期: 現(xiàn)貨
- 價(jià)格與訂購(gòu): 7500
- 數(shù)量:
- 規(guī)格: 1mg
- 產(chǎn)品信息
- 如何訂購(gòu)
產(chǎn)品描述
Mirvetuximab soravtansine (IMGN853) 是一種抗體藥物偶聯(lián)物 (ADC),由細(xì)胞毒性 maytansoid DM4 組成,共價(jià)連接到人源化單克隆抗體 M9346A。Mirvetuximab soravtansine 選擇性結(jié)合葉酸受體1 (FOLR1)。Mirvetuximab soravtansine 具有抑制生長(zhǎng)和增強(qiáng) DNA 損傷的抗增殖作用。
生物活性
Mirvetuximab soravtansine (IMGN853) is an antibody drug-conjugate (ADC) consisting of the cytotoxic maytansinoid, DM4, covalently linked to the humanized monoclonal antibody M9346A. Mirvetuximab soravtansine selectively binds to folate receptor 1 (FOLR1). Mirvetuximab soravtansine has an anti-proliferative effect via growth arrest and augmented DNA damage.
體外研究(In Vitro)
Mirvetuximab soravtansine (IMGN853; 8 nM; 6 h; IGROV-1 細(xì)胞) 與 Carboplatin (HY-17393) 的結(jié)合在體外促進(jìn)協(xié)同生長(zhǎng)抑制作用和細(xì)胞周期擾動(dòng)。
體內(nèi)研究(In Vivo)
Mirvetuximab soravtansine (IMGN853; 5 mg/kg; i.v.; SCID 雌性小鼠患者來(lái)源的異種移植模型) 增強(qiáng) Carboplatin 的體內(nèi)抗腫瘤活性。
性狀
液體icon
CAS 號(hào)
1453084-37-1
運(yùn)輸條件
Shipping with dry ice.
CAS 號(hào)
572-03-2
icon
儲(chǔ)存方式
-80°C, protect from light
純度
99.90%
參考文獻(xiàn)
[1]. Ponte JF, et, al. Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models. Neoplasia. 2016 Dec;18(12):775-784.
iconicon
Note
For research use only .